Scientists develop new compound which kills both types of antibiotic resistant superbugs
- A new compound developed by University of Sheffield experts has killed antibiotic resistant bacteria, such as MRSA and E.Coli, during tests
- The compound has been able to kill both classes of bacteria, gram-negative and gram-positive
- Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.
- The research could pave the way for much needed new treatments for antibiotic resistant superbugs
Researchers at the University of Sheffield have developed a new compound that is able to kill both gram-positive and gram-negative antibiotic-resistant bacteria.
Gram-positive and gram-negative bacteria have different cell wall structures, but the new antibiotic compound is able to pass through the cell wall of both forms of bacteria and then bind to the DNA.
The findings, published in Chemical Science, pave the way for developing new treatments for all kinds of antibiotic resistant bacteria, including the gram-positive MRSA and gram-negative E.Coli.
The team from the University of Sheffield has previously developed new compound leads that specifically target gram-negative bacteria, but this new compound is a broad spectrum antimicrobial which means it is just as effective in both types of bacteria.
Gram-negative bacteria strains are particularly difficult to treat as their cell wall prevents drugs from getting into the microbe, they can cause infections including pneumonia, urinary tract infections and bloodstream infections.
The team worked with colleagues at the Science and Technology Facilities Council’s (STFC) Rutherford Appleton Laboratory (RAL).
Professor Jim Thomas, Principal Investigator of the research from the University of Sheffield, said: “Antimicrobial resistance is an increasing problem with many studies predicting a medical global emergency, so broad spectrum antimicrobials which work against resistant pathogens are urgently needed.
“As the compound is luminescent it glows when exposed to light. This means we were able to follow the uptake and effect on bacteria using advanced microscopy techniques available at STFC's Rutherford Appleton Lab.
Antimicrobial resistance is already responsible for 25,000 deaths in the EU each year, and unless this rapidly emerging threat is addressed, it’s estimated by 2050 more than 10 million people could die every year due to antibiotic resistant infections.
Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.
The University of Sheffield’s Department of Chemistry has a rich history of excellent research and inspirational teaching. Research spans photophysical and biophysical chemistry, polymers, nanomaterials, theory, organic chemistry and chemical biology. This provides the basis for a substantial and varied portfolio of research grants, collaborations with industry, and research institution partnerships.
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For further information please contact:
Media and PR Assistant
The University of Sheffield
0114 222 1034